Systemic Scleroderma
Scleroderma is not one disease — it is a coordinated systemic challenge. Lung, GI, vascular, renal, and skin each move on their own timeline. The synthesis is everything.
What we mean when we say Systemic Sclerosis.
Systemic Sclerosis (SSc), commonly called Systemic Scleroderma, is a rare autoimmune connective tissue disease characterized by vascular dysfunction, immune dysregulation, and progressive fibrosis of the skin and internal organs. It is classified into limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) subtypes, each with distinct trajectories and complication patterns.
The clinical landscape spans Raynaud's phenomenon, digital ulcers, interstitial lung disease (the leading cause of mortality), pulmonary arterial hypertension, GI dysmotility (esophagus, gastric, small bowel, colon, anorectum), scleroderma renal crisis, and cardiac involvement. Each organ system requires its own surveillance protocol and intervention thresholds.
Standard care is anchored in rheumatology but inevitably requires coordination across pulmonology, GI, cardiology, nephrology, and vascular medicine. The synthesis is rarely complete.
Approximately 18.87 per 100,000 globally — roughly 1.47 million people worldwide. Strong female predominance.
Why Systemic Sclerosis gets missed.
Systemic Scleroderma is rarely missed at diagnosis — the skin findings, Raynaud's, and antibody patterns get the attention they need from rheumatology. The gap is in what comes after. Scleroderma is a coordinated systemic challenge across lung, heart, GI, kidney, and vascular domains, and most patients don't have a single clinician synthesizing across all of them.
- 01Interstitial lung disease is the leading cause of scleroderma mortality, and ILD progression risk stratification is the highest-leverage decision in many cases. Yet the surveillance — HRCT, PFT, DLCO trend — is inconsistently coordinated, and decisions about mycophenolate, tocilizumab, nintedanib, and autologous stem cell transplant are often made without systematic literature integration.
- 02Pulmonary arterial hypertension screening is uneven. Echocardiographic screening and right heart catheterization are condition-appropriate, but in practice they happen at variable intervals and often only after symptoms develop.
- 03GI dysmotility — esophageal, gastric, small bowel, colonic, anorectal — is nearly universal in systemic sclerosis and rarely fully characterized. Most patients are managed for esophageal reflux without evaluation of the rest of the GI tract.
- 04Scleroderma renal crisis prevention and Raynaud's / digital ulcer management are areas where evidence-based intervention is well-established but inconsistently applied. ACE inhibitor strategy, calcium channel blocker selection, and IV iloprost or bosentan considerations vary by center.
The Ternary Health approach to Systemic Scleroderma.
Coordinate the multi-organ surveillance plan — pulmonary, cardiac, GI, renal, vascular — across the specific subtype (limited versus diffuse cutaneous) and autoantibody profile, rather than evaluating each organ in isolation.
Stratify ILD progression risk specifically and audit the treatment selection — mycophenolate, tocilizumab, nintedanib, and autologous stem cell transplant — against current evidence and your specific trajectory.
Characterize the GI dysmotility picture fully — manometry, scintigraphy, and small bowel evaluation where indicated — rather than managing as esophageal reflux alone. The full GI picture matters for nutrition, medication absorption, and quality of life.
Build the integrated medication and supplement plan. Immunosuppression interacts with PAH-directed therapy, with vascular agents, with GI prokinetics, and with the dietary and supplement landscape patients are often navigating on their own.
The Ternary Signal Library for Systemic Sclerosis.
Our Signal Library for Systemic Scleroderma codifies the specific patterns that matter — autoantibody and subtype findings, pulmonary and cardiac surveillance, GI dysmotility and renal markers, and vascular progression patterns. Your case is mapped against these signals; each present signal is identified and prioritized for your presentation.
- —ANA pattern — centromere, nucleolar, speckled
- —Specific antibodies — anti-Scl-70 (topoisomerase I), anti-centromere, anti-RNA polymerase III
- —Limited versus diffuse cutaneous classification
- —Modified Rodnan skin score trajectory
- —Overlap features — myositis, Sjögren's, mixed connective tissue disease
- —HRCT — ILD pattern, extent, fibrosis distribution
- —PFT trend — FVC, DLCO, restrictive pattern characterization
- —Echocardiogram — RV function, PAP estimation
- —Right heart catheterization where PAH screening positive
- —Cardiac MRI for myocardial fibrosis where indicated
- —Esophageal manometry and pH studies
- —Gastric emptying study where suspected
- —Small bowel evaluation — SIBO testing, manometry where available
- —Anorectal manometry where fecal incontinence present
- —Renal function trend and hypertension monitoring for scleroderma renal crisis
- —Raynaud's frequency, severity, and trigger pattern
- —Digital ulcer history and current status
- —Nailfold capillaroscopy findings where performed
- —Vasodilator and antiplatelet trial history
- —Calcinosis distribution and management considerations
How a Systemic Sclerosis case moves through our workflow.
Our nine-stage workflow is the same for every engagement. What changes per condition is the content at each stage — the records we pull, the signals we apply, the specialists we map, the pathways we evaluate. Below, how your case specifically would move through each stage.
What you receive.
- —A written case synthesis covering subtype, antibody profile, and multi-organ involvement
- —Integration of pulmonary, cardiac, GI, renal, and vascular findings into a single view
- —ILD progression risk stratification with treatment selection framework (mycophenolate, tocilizumab, nintedanib, ASCT)
- —PAH and renal crisis surveillance schedule with intervention thresholds
- —GI dysmotility characterization and management plan across the full GI tract
- —Raynaud's, digital ulcer, and calcinosis management framework
- —Specialist identification for scleroderma centers and indicated organ specialists
- —A written action plan and follow-up support as you implement it
What a Precision Deep Dive provides for Systemic Sclerosis.
A Ternary Health Precision Deep Dive for systemic scleroderma synthesizes the multi-organ surveillance and management plan: ILD progression risk stratification and treatment selection (mycophenolate, tocilizumab, nintedanib, autologous stem cell transplant evidence), PAH screening, GI dysmotility characterization, Raynaud's and digital ulcer management, renal crisis prevention, and supplement and medication interaction review.
See the published sample reports · read the Ternary Method
What we look for alongside Systemic Sclerosis.
Patients with Systemic Scleroderma frequently present with one or more of the following. Ternary reports evaluate the full picture rather than the condition in isolation.
- Interstitial lung disease
- Pulmonary arterial hypertension
- Gastroparesis and broader GI dysmotility
- Scleroderma renal crisis
- Sjögren's syndrome overlap
- Cardiac involvement
What prospective Systemic Scleroderma clients ask most.
Three ways to engage Ternary on Systemic Sclerosis.
From a free starting point to a full personalized action plan — three tiers, one methodology, all tailored to Systemic Sclerosis.
Free Brief
A 3–5 page personalized starting point on your condition. Most relevant labs, specialist categories, first decisions worth pursuing. No charge.
Generated instantly, no charge.
Get a free Brief→Launchpad
A research-based preparedness guide. Current literature, realistic prognosis, test and treatment categories worth exploring, and a checklist of what you might consider to better manage and understand your condition.
Delivered in 3–5 business days
Start a Launchpad→Precision Deep Dive
A vigorously researched and highly personalized action plan: the specialists and centers of excellence worth considering, evidence-graded options, and a prioritized set of questions to raise — all curated for your specific condition and lifestyle, for you and your physicians to weigh together. The plan includes 30 days of follow-up support and tailored insights into how best to navigate your situation now and in the future.
September 2026 cohort
Apply for a Deep Dive→See exactly what you receive.
A composite sample illustrating the structure and depth of every Ternary Health Precision Deep Dive. Same universal 17-section format used for Systemic Sclerosis — drawn from four research-validated patient profiles across four conditions.
Every Ternary engagement produces a report with the same architecture: client profile, applied methodology, signal analysis, lab and genetic findings, imaging synthesis, disease model, intervention prioritization, specialist pathway, staged medical therapy, 90-day roadmap, and monitoring cadence. The composite shows you exactly how that architecture renders.
Ready for clarity on your Systemic Sclerosis?
Applications for the September 2026 cohort are open now and reviewed in the order received. Not ready? A free Ternary Brief on Systemic Sclerosis is generated instantly, no charge.